Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastoma
暂无分享,去创建一个
S. Bakas | C. Davatzikos | H. Akbari | R. Shinohara | R. Verma | S. Brem | D. O’Rourke | A. Fathi Kazerooni | C. Koumenis | Sanjay Saxena | S. Mohan | M. Nasrallah | R. Lustig | T. Ganguly | C. Sako | E. Mamourian | S. Bagley | A. Desai | Danni Tu | I. Verginadis | Erik Toorens | V. Bashyam | Anahita Fathi Kazerooni
[1] J. Malter,et al. Alterations in the RB Pathway With Inactivation of RB1 Characterize Glioblastomas With a Primitive Neuronal Component. , 2021, Journal of neuropathology and experimental neurology.
[2] S. Bakas,et al. Applications of Radiomics and Radiogenomics in High-Grade Gliomas in the Era of Precision Medicine , 2021, Cancers.
[3] Anna Luisa Di Stefano,et al. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities , 2021, Nature Cancer.
[4] R. Verhaak,et al. New hints towards a precision medicine strategy for IDH wild-type Glioblastoma. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] S. Bakas,et al. Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review , 2020, Journal of magnetic resonance imaging : JMRI.
[6] Siddhesh P. Thakur,et al. Brain extraction on MRI scans in presence of diffuse glioma: Multi-institutional performance evaluation of deep learning methods and robust modality-agnostic training☆ , 2020, NeuroImage.
[7] Christos Davatzikos,et al. Overall survival prediction in glioblastoma patients using structural magnetic resonance imaging (MRI): advanced radiomic features may compensate for lack of advanced MRI modalities , 2020, Journal of medical imaging.
[8] Christos Davatzikos,et al. AI-based Prognostic Imaging Biomarkers for Precision Neurooncology: the ReSPOND Consortium. , 2020, Neuro-oncology.
[9] R. Steenbakkers,et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. , 2020, Radiology.
[10] Christos Davatzikos,et al. Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma , 2020, JCO clinical cancer informatics.
[11] Christos Davatzikos,et al. The Cancer Imaging Phenomics Toolkit (CaPTk): Technical Overview , 2019, BrainLes@MICCAI.
[12] Jeffrey H. Chuang,et al. LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS , 2019, Nature.
[13] Lena Maier-Hein,et al. BIAS: Transparent reporting of biomedical image analysis challenges , 2019, Medical Image Analysis.
[14] Patrick C. Staples,et al. An Online Calculator for the Prediction of Survival in Glioblastoma Patients Using Classical Statistics and Machine Learning , 2019, Neurosurgery.
[15] Bjarne Winther Kristensen,et al. Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma , 2019, Neuro-oncology practice.
[16] Christian Desrosiers,et al. Integration of Radiomic and Multi-omic Analyses Predicts Survival of Newly Diagnosed IDH1 Wild-Type Glioblastoma , 2019, Cancers.
[17] Lorenzo Trippa,et al. Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data , 2019, Clinical Cancer Research.
[18] Zev A. Binder,et al. Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma , 2019, Academic pathology.
[19] A. Bentivegna,et al. Role of Notch Signaling Pathway in Glioblastoma Pathogenesis , 2019, Cancers.
[20] M. Gilbert,et al. MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials , 2018, Clinical Cancer Research.
[21] Seok-Gu Kang,et al. Radiomic MRI Phenotyping of Glioblastoma: Improving Survival Prediction. , 2018, Radiology.
[22] Jennie W. Taylor,et al. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma , 2018, Journal of Neuro-Oncology.
[23] Raymond Y Huang,et al. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma , 2018, Neuro-oncology.
[24] Christos Davatzikos,et al. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. , 2018, Cancer cell.
[25] David T. W. Jones,et al. Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma , 2018, Neuro-oncology.
[26] Alejandro F. Frangi,et al. Characterization of active and infiltrative tumorous subregions from normal tissue in brain gliomas using multiparametric MRI , 2018, Journal of magnetic resonance imaging : JMRI.
[27] F. Lieberman,et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.
[28] G. Reifenberger,et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.
[29] Jennie W. Taylor,et al. Clinical trial endpoints for patients with gliomas. , 2017, Neuro-oncology practice.
[30] B. Taylor,et al. Implementing Genome-Driven Oncology , 2017, Cell.
[31] Stefan Leger,et al. Image biomarker standardisation initiative version 1 . 4 , 2016, 1612.07003.
[32] M. Cecchini,et al. Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease , 2016, Scientific Reports.
[33] Prateek Prasanna,et al. Co-occurrence of Local Anisotropic Gradient Orientations (CoLlAGe): A new radiomics descriptor , 2016, Scientific Reports.
[34] Paul A. Yushkevich,et al. FAST AUTOMATIC SEGMENTATION OF HIPPOCAMPAL SUBFIELDS AND MEDIAL TEMPORAL LOBE SUBREGIONS IN 3 TESLA AND 7 TESLA T2-WEIGHTED MRI , 2016, Alzheimer's & Dementia.
[35] Konstantinos Kamnitsas,et al. Efficient multi‐scale 3D CNN with fully connected CRF for accurate brain lesion segmentation , 2016, Medical Image Anal..
[36] Luke Macyszyn,et al. Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques. , 2016, Neuro-oncology.
[37] D. Owens,et al. Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials. , 2016, Primary care diabetes.
[38] Jerzy K. Kulski,et al. Next-Generation Sequencing — An Overview of the History, Tools, and “Omic” Applications , 2016 .
[39] Paul Kinahan,et al. Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.
[40] S. South,et al. DNA copy number analysis of Grade II–III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status , 2015, Acta neuropathologica communications.
[41] Andrew Zisserman,et al. Very Deep Convolutional Networks for Large-Scale Image Recognition , 2014, ICLR.
[42] Scott N. Hwang,et al. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. , 2014, Radiology.
[43] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[44] Giovanni Tesoriere,et al. RB1 in cancer: Different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis , 2013, Journal of cellular physiology.
[45] David Gutman,et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. , 2013, Radiology.
[46] Geoffrey E. Hinton,et al. ImageNet classification with deep convolutional neural networks , 2012, Commun. ACM.
[47] Keith Paulsen,et al. Genetics of glioblastoma: a window into its imaging and histopathologic variability. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.
[48] A. Capobianco,et al. Notch signalling in solid tumours: a little bit of everything but not all the time , 2011, Nature Reviews Cancer.
[49] Trevor Hastie,et al. Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. , 2011, Journal of statistical software.
[50] D. Scheie,et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme , 2010, Acta neurologica Scandinavica.
[51] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[52] Adolf Pfefferbaum,et al. The SRI24 multichannel atlas of normal adult human brain structure , 2009, Human brain mapping.
[53] Richard Simon,et al. Bias in error estimation when using cross-validation for model selection , 2006, BMC Bioinformatics.
[54] Christos Davatzikos,et al. Cancer imaging phenomics toolkit: quantitative imaging analytics for precision diagnostics and predictive modeling of clinical outcome , 2018, Journal of medical imaging.
[55] G. Reifenberger,et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.
[56] David A. Glanzer,et al. Technical Overview , 2008 .